Translations:Obesity/67/en: Difference between revisions

From Azupedia
Jump to navigation Jump to search
VisualWikitext
FuzzyBot (talk | contribs)
15,079 edits
Importing a new version from external source
Tags: Mobile edit Mobile web edit
 
(No difference)

Latest revision as of 14:18, 5 March 2024

Information about message (contribute)
This message has no documentation. If you know where or how this message is used, you can help other translators by adding documentation to this message.
Message definition (Obesity)
In 2019 a [[systematic review]] compared the effects on weight of various doses of [[fluoxetine]] (60 mg/d, 40 mg/d, 20 mg/d, 10 mg/d) in obese adults. When compared to placebo, all dosages of fluoxetine appeared to contribute to weight loss but lead to increased risk of experiencing side effects such as dizziness, drowsiness, fatigue, insomnia and nausea during period of treatment. However, these conclusions were from low certainty evidence. When comparing, in the same review, the effects of fluoxetine on weight of obese adults, to other [[Anorectic|anti-obesity agents]], [[Omega-3 fatty acid|omega-3]] gel and not receiving a treatment, the authors could not reach conclusive results due to poor quality of evidence.

In 2019 a systematic review compared the effects on weight of various doses of fluoxetine (60 mg/d, 40 mg/d, 20 mg/d, 10 mg/d) in obese adults. When compared to placebo, all dosages of fluoxetine appeared to contribute to weight loss but lead to increased risk of experiencing side effects such as dizziness, drowsiness, fatigue, insomnia and nausea during period of treatment. However, these conclusions were from low certainty evidence. When comparing, in the same review, the effects of fluoxetine on weight of obese adults, to other anti-obesity agents, omega-3 gel and not receiving a treatment, the authors could not reach conclusive results due to poor quality of evidence.

Retrieved from "https://wiki.tiffa.net/w/index.php?title=Translations:Obesity/67/en&oldid=124620"